DK2691413T3 - Makrocykliske forbindelser og fremgangsmåder til fremstilling deraf - Google Patents
Makrocykliske forbindelser og fremgangsmåder til fremstilling deraf Download PDFInfo
- Publication number
- DK2691413T3 DK2691413T3 DK12716539T DK12716539T DK2691413T3 DK 2691413 T3 DK2691413 T3 DK 2691413T3 DK 12716539 T DK12716539 T DK 12716539T DK 12716539 T DK12716539 T DK 12716539T DK 2691413 T3 DK2691413 T3 DK 2691413T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- compound according
- alkyl
- mmol
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Claims (17)
1. Forbindelse med formlen (I):
Formel (I) i hvilken: molekyldelen Xi betyder -OR1, -NR1R2 eller R3; Ri, R2 og R3 uafhængigt betyder alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkyl-cycloalkyl, alkylcycloalkenyl, alkenylcycloalkyl, alkenylcycloalkenyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkenylaryl eller alkenylheteroaryl, hvor enhver af disse grupper eventuelt kan være substitueret med monocyklisk aryl eller monocyklisk heteroaryl; og hvor ét eller flere carbonatomer i R1; R2 og R3, der ikke udgør en del af en aryl- eller heteroarylgruppe, eventuelt er erstattet med et heteroatom valgt fra O, N og S(0)p, hvor p betyder 0, 1 eller 2, og hvor ét eller flere carbonatomer i Ri, R2 og R3 eventuelt er erstattet med carbonyl; eller R-ι og R2 er forbundet således, at NR^ betyder en mættet eller umættet heterocyklisk ring indeholdende det specificerede nitrogenatom, og hvor ét eller flere carbonatomer i ringen eventuelt er erstattet med et yderligere heteroatom valgt fra O, N og S(0)p, hvor p betyder 0, 1 eller 2, og hvor ét eller flere carbonatomer i ringen eventuelt er erstattet med carbonyl, og den heterocykliske ring eventuelt kan være kondenseret til en aryl- eller heteroarylring; og hvor ét eller flere carbonatomer i en Ri -, R2- og R3- gruppe eventuelt kan være substitueret med ét eller flere halogenatomer; eller Ri og/eller R2 betyder hydrogen; R9 betyder H eller OH; n betyder en enkelt- eller dobbeltbinding, bortset fra, at når n betyder en dobbeltbinding, betyder R9 H; FU, R5, Re, R7 og Rs uafhængigt betyder H, F, Cl, Br, alkenyl eller alkyl, hvor ét eller flere carbonatomer i alkylgruppen eventuelt er erstattet med et heteroatom valgt fra O, N og S(0)p, hvor p betyder 0,1 eller 2, og hvor ét eller flere carbonatomer i alkylgruppen eventuelt er erstattet med carbonyl, og alkylgruppen eventuelt kan være substitueret med ét eller flere halogenatomer; X2, X3, X4, X5 og X6 uafhængigt betyder C eller N, og såfremt enhver af disse grupper betyder N, er den tilknyttede substituent fraværende; med det forbehold, at når R4, R8, R7 og R8 alle betyder H, og X2, X3, X4, X5 og X6 alle betyder C, kan R5 ikke betyde OH, -Oalkyl eller -0(C0)alkyl; herunder enhver tautomer deraf; og omfattende et methanoladditionsprodukt deraf, hvori en ketal er dannet ved kombination af C-53-ketogruppen og C-15- hydroxylgruppen og methanol; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvori n betyder en enkeltbinding.
3. Forbindelse ifølge krav 1 eller krav 2, hvori R9 betyder OH.
4. Forbindelse ifølge ethvert af kravene 1 til 3, hvori R5 betyder OH.
5. Forbindelse ifølge ethvert af kravene 1 til 4, hvori R6 betyder H, Me eller F.
6. Forbindelse ifølge ethvert af kravene 1 til 5, hvori R7 betyder H eller F.
7. Forbindelse ifølge ethvert af kravene 1 til 6, hvori R6 og/eller R7 betyder F.
8. Forbindelse ifølge ethvert af kravene 1 til 7, hvori X1 betyder NRiR2.
9. Forbindelse ifølge krav 8, hvori Ri betyder alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkyl, alkenylcycloalkenyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkenylaryl eller alkenylheteroaryl, og R2 betyder H, alkyl, alkenyl eller -Oalkyl.
10. Forbindelse ifølge krav 8, hvori NR1R2 betyder morpholinyl, oxazinan eller én af grupperne vist i følgende tabel:
11. Forbindelse ifølge krav 1 valgt fra:
herunder enhver tautomer deraf; eller en isomer deraf, hvori C26, 27 C=C-bin-dingen vist som trans er cis; og omfattende et mehanoladditionsprodukt deraf, hvori en ketal er dannet ved kombination af C-53 ketogruppen (såfremt den er til stede) og C-15 hydroxylgruppen og methanol; eller et farmaceutisk acceptabelt salt deraf.
12. Forbindelse ifølge ethvert af kravene 1 til 11 til anvendelse som et farmaceutisk middel.
13. Forbindelse ifølge ethvert af kravene 1 til 11 til anvendelse som et farmaceutisk middel til behandling af virale infektioner såsom HCV- eller HIV-infektion eller som et immunosuppressivt middel eller et antiinflammatorisk middel.
14. Farmaceutisk sammensætning indeholdende en forbindelse ifølge ethvert af kravene 1 til 11 sammen med et farmaceutisk acceptabelt fortyndingsmiddel eller bærestof.
15. Farmaceutisk sammensætning indeholdende en forbindelse ifølge ethvert af kravene 1 til 11 sammen med et farmaceutisk acceptabelt fortyndingsmiddel eller bærestof, yderligere omfattende en anden eller yderligere aktiv bestanddel.
16. Fremgangsmåde til fremstilling af en forbindelse ifølge ethvert af kravene 1 til 11, hvilken fremgangsmåde omfatter omsætning af en forbindelse med formlen V
Formel V i hvilken X1 er som defineret i ethvert af kravene 1 til 11, og hvert Ru uafhængigt er Ci-4 alkyl eller benzyl; med en aldehydisk makrocyklisk forbindelse (forbindelse med formlen VI):
hvori X2, X3, X4, X5, Xe, R4, Rs, Re, R7, Rs, Rg og n er som defineret i ethvert af kravene 1 til 11.
17. Forbindelse med formlen (VI):
hvori X2, X3, X4, X5, Xe, R4, Rs, Re, R7, Rs, Rg og n er som defineret i ethvert af kravene 1 til 11.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105293.3A GB201105293D0 (en) | 2011-03-29 | 2011-03-29 | Novel compounds and methods for their production |
| GBGB1113629.8A GB201113629D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
| GBGB1202060.8A GB201202060D0 (en) | 2012-02-07 | 2012-02-07 | Novel compounds and methods for their production |
| PCT/GB2012/050707 WO2012131377A1 (en) | 2011-03-29 | 2012-03-29 | Macrocyclic compounds and methods for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2691413T3 true DK2691413T3 (da) | 2015-04-07 |
Family
ID=46001313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12716538T DK2691412T3 (da) | 2011-03-29 | 2012-03-29 | Makrocyklisk forbindelse og fremgangsmåder til fremstilling deraf |
| DK12716539T DK2691413T3 (da) | 2011-03-29 | 2012-03-29 | Makrocykliske forbindelser og fremgangsmåder til fremstilling deraf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12716538T DK2691412T3 (da) | 2011-03-29 | 2012-03-29 | Makrocyklisk forbindelse og fremgangsmåder til fremstilling deraf |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9090657B2 (da) |
| EP (2) | EP2691412B1 (da) |
| JP (2) | JP6118793B2 (da) |
| KR (2) | KR101868084B1 (da) |
| CN (3) | CN107417766A (da) |
| AR (1) | AR085724A1 (da) |
| AU (2) | AU2012235961B2 (da) |
| BR (2) | BR112013024974A2 (da) |
| CA (2) | CA2830827C (da) |
| CL (2) | CL2013002740A1 (da) |
| CY (2) | CY1116318T1 (da) |
| DK (2) | DK2691412T3 (da) |
| EA (2) | EA023907B1 (da) |
| ES (2) | ES2533437T3 (da) |
| HK (2) | HK1189236A1 (da) |
| HR (2) | HRP20150187T1 (da) |
| IL (2) | IL228508B (da) |
| JO (1) | JO3063B1 (da) |
| MX (2) | MX345352B (da) |
| MY (2) | MY170618A (da) |
| PL (2) | PL2691413T3 (da) |
| PT (2) | PT2691413E (da) |
| RS (2) | RS53963B1 (da) |
| SG (2) | SG193569A1 (da) |
| SI (2) | SI2691412T1 (da) |
| TW (1) | TWI525098B (da) |
| UY (1) | UY33993A (da) |
| WO (2) | WO2012131371A1 (da) |
| ZA (2) | ZA201307149B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012019866A8 (pt) | 2010-02-09 | 2017-12-26 | Biotica Tech Limited | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| CN103130734A (zh) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | 一种合成1,2-吗啉盐酸盐的方法 |
| CN105695541B (zh) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | 一种抗生素nvp018中间体的分离纯化方法 |
| KR20180036522A (ko) * | 2016-09-30 | 2018-04-09 | (주)나노믹스 | 스틸벤 유도체 및 그 제조 방법 |
| EP3541388A1 (en) * | 2016-11-18 | 2019-09-25 | Neurovive Pharmaceutical AB | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
| CN112410353B (zh) * | 2019-08-23 | 2023-01-24 | 上海医药工业研究院 | 一种fkbS基因、含其的基因工程菌及其制备方法和用途 |
| CN115028681B (zh) * | 2022-08-11 | 2022-11-15 | 中国科学院微生物研究所 | 一种降解亲环素a的嵌合体化合物及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| RU2427372C2 (ru) | 2005-06-17 | 2011-08-27 | Новартис Аг | Применение санглиферина для лечения вируса гепатита с |
| JP5801534B2 (ja) | 2007-01-04 | 2015-10-28 | デビオファーム インターナショナル ソシエテ アノニム | ウールリッヒ型先天筋ジストロフィーの処置のための、非免疫抑制性シクロスポリン |
| CN102224242B (zh) | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
| CN101691575B (zh) * | 2008-09-24 | 2013-06-05 | 中国科学院上海有机化学研究所 | 一种萨菲菌素的生物合成基因簇 |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| BR112012019866A8 (pt) * | 2010-02-09 | 2017-12-26 | Biotica Tech Limited | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto |
| WO2011098805A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| CA3028414C (en) * | 2010-12-20 | 2021-01-26 | Neurovive Pharmaceutical Ab | Sanglifehrin derivatives and methods for their production |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2012
- 2012-03-12 JO JOP/2012/0053A patent/JO3063B1/ar active
- 2012-03-28 AR ARP120101043A patent/AR085724A1/es unknown
- 2012-03-28 TW TW101110673A patent/TWI525098B/zh not_active IP Right Cessation
- 2012-03-29 PL PL12716539T patent/PL2691413T3/pl unknown
- 2012-03-29 ES ES12716538.9T patent/ES2533437T3/es active Active
- 2012-03-29 BR BR112013024974A patent/BR112013024974A2/pt not_active Application Discontinuation
- 2012-03-29 DK DK12716538T patent/DK2691412T3/da active
- 2012-03-29 EA EA201391396A patent/EA023907B1/ru not_active IP Right Cessation
- 2012-03-29 AU AU2012235961A patent/AU2012235961B2/en not_active Ceased
- 2012-03-29 US US13/433,944 patent/US9090657B2/en active Active
- 2012-03-29 JP JP2014501720A patent/JP6118793B2/ja active Active
- 2012-03-29 PT PT127165397T patent/PT2691413E/pt unknown
- 2012-03-29 CN CN201611126823.4A patent/CN107417766A/zh active Pending
- 2012-03-29 UY UY0001033993A patent/UY33993A/es not_active Application Discontinuation
- 2012-03-29 CA CA2830827A patent/CA2830827C/en not_active Expired - Fee Related
- 2012-03-29 SI SI201230145T patent/SI2691412T1/sl unknown
- 2012-03-29 PL PL12716538T patent/PL2691412T3/pl unknown
- 2012-03-29 US US14/006,341 patent/US9139613B2/en active Active
- 2012-03-29 KR KR1020137027773A patent/KR101868084B1/ko active IP Right Grant
- 2012-03-29 MY MYPI2013701789A patent/MY170618A/en unknown
- 2012-03-29 BR BR112013024965A patent/BR112013024965A2/pt not_active Application Discontinuation
- 2012-03-29 WO PCT/GB2012/050700 patent/WO2012131371A1/en active Application Filing
- 2012-03-29 EP EP12716538.9A patent/EP2691412B1/en active Active
- 2012-03-29 CN CN201280026190.3A patent/CN103619869B/zh not_active Expired - Fee Related
- 2012-03-29 RS RS20150161A patent/RS53963B1/en unknown
- 2012-03-29 SG SG2013070974A patent/SG193569A1/en unknown
- 2012-03-29 AU AU2012235880A patent/AU2012235880B2/en not_active Ceased
- 2012-03-29 JP JP2014501719A patent/JP6118792B2/ja not_active Expired - Fee Related
- 2012-03-29 PT PT127165389T patent/PT2691412E/pt unknown
- 2012-03-29 ES ES12716539.7T patent/ES2533438T3/es active Active
- 2012-03-29 EP EP12716539.7A patent/EP2691413B1/en active Active
- 2012-03-29 EA EA201391399A patent/EA023848B1/ru not_active IP Right Cessation
- 2012-03-29 KR KR1020137028095A patent/KR101911484B1/ko active IP Right Grant
- 2012-03-29 RS RS20150162A patent/RS53964B1/en unknown
- 2012-03-29 MX MX2013011051A patent/MX345352B/es active IP Right Grant
- 2012-03-29 CN CN201280026793.3A patent/CN103635484B/zh active Active
- 2012-03-29 DK DK12716539T patent/DK2691413T3/da active
- 2012-03-29 MY MYPI2013701788A patent/MY170637A/en unknown
- 2012-03-29 MX MX2013011043A patent/MX345351B/es active IP Right Grant
- 2012-03-29 CA CA2830831A patent/CA2830831C/en not_active Expired - Fee Related
- 2012-03-29 WO PCT/GB2012/050707 patent/WO2012131377A1/en active Application Filing
- 2012-03-29 SI SI201230146T patent/SI2691413T1/sl unknown
- 2012-03-29 SG SG2013070966A patent/SG193568A1/en unknown
-
2013
- 2013-09-17 IL IL228508A patent/IL228508B/en active IP Right Grant
- 2013-09-17 IL IL228509A patent/IL228509B/en active IP Right Grant
- 2013-09-23 ZA ZA2013/07149A patent/ZA201307149B/en unknown
- 2013-09-25 CL CL2013002740A patent/CL2013002740A1/es unknown
- 2013-09-25 CL CL2013002739A patent/CL2013002739A1/es unknown
- 2013-09-26 ZA ZA2013/07231A patent/ZA201307231B/en unknown
-
2014
- 2014-02-13 HK HK14101335.6A patent/HK1189236A1/xx not_active IP Right Cessation
- 2014-02-13 HK HK14101336.5A patent/HK1189237A1/xx not_active IP Right Cessation
-
2015
- 2015-02-17 HR HRP20150187TT patent/HRP20150187T1/hr unknown
- 2015-02-17 HR HRP20150184TT patent/HRP20150184T1/hr unknown
- 2015-02-27 CY CY20151100207T patent/CY1116318T1/el unknown
- 2015-03-06 CY CY20151100236T patent/CY1116186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2691413T3 (da) | Makrocykliske forbindelser og fremgangsmåder til fremstilling deraf | |
| CA2788761C (en) | Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv | |
| CA2822347C (en) | Sanglifehrin derivatives and methods for their production | |
| WO2011098805A1 (en) | Sanglifehrin based compounds | |
| Class et al. | Patent application title: Macrocyclic Compounds and Methods for Their Production Inventors: Steven James Moss (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Barrie Wilkinson (Cambridge, GB) Assignees: NeuroVive Pharmaceutical AB | |
| AU2011346823B8 (en) | Sanglifehrin derivatives and methods for their production |